
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Termination
Details : MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Termination

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by I...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $230.0 million
October 04, 2021
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Details : In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
August 12, 2020
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020
Details : Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Theradex
Deal Size : Inapplicable
Deal Type : Inapplicable
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 18, 2019
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Theradex
Deal Size : Inapplicable
Deal Type : Inapplicable

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Adenocarcinoma of Lung.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 26, 2019

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pharm-Olam
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 16, 2015
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pharm-Olam
Deal Size : Inapplicable
Deal Type : Inapplicable

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 05, 2014

 Reset All
Reset All